Information Provided By:
Fly News Breaks for August 24, 2018
Aug 24, 2018 | 07:31 EDT
Canaccord analyst Kyle Rose initiated Misonix with a Buy rating as he believes it has the makings of a classic micro/small-cap med-tech execution story, with an established technology, strong pipeline, and large TAM underpinning the transition to a direct sales channel and recurring revenue business model. Rose has a $24 price target on Misonix shares.
News For MSON From the Last 2 Days
There are no results for your query MSON